Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial.

Robert W Summers1, David E Elliott, Joseph F Urban

  • 1James A. Clifton Center for Digestive Diseases, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242, USA. robert-summers@uiowa.edu

Gastroenterology
|April 13, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Business of Recovery: Understanding Operational Costs and Funding Sources in Recovery Housing in the United States.

Substance use & addiction journal·2026
Same author

Helminth exposure influences Th17 plasticity, suppressing inflammatory and promoting regulatory activity by Th17 lineage cells.

Frontiers in immunology·2026
Same author

Fruit and Vegetable Supplemented-Diet Ameliorates Dextran Sodium Sulfate (DSS)-Induced Colitis by Modulating Host Transcriptome and Gut Metagenome Response.

Nutrients·2026
Same author

Inflammatory ILC2s migrate to distal tissues during infection using stage-specific S1P receptors.

Science immunology·2026
Same author

Barriers and facilitators to recovery support interventions in US Rural Recovery Houses: Implementing the SMART life skills program.

Evaluation and program planning·2025
Same author

Transcriptional responses of mouse proximal colon and colonoids during early whipworm infection.

mBio·2025

Therapy with Trichuris suis ova shows promise for treating ulcerative colitis. This helminth treatment was found to be safe and effective in improving disease activity in patients with active colitis.

Area of Science:

  • Gastroenterology
  • Immunology
  • Parasitology

Background:

  • Ulcerative colitis (UC) prevalence is higher in industrialized nations, contrasting with lower rates in regions with frequent helminth infections.
  • Helminths modulate the immune system, inducing regulatory T cells and cytokines, which may protect against or ameliorate colitis.
  • Animal models suggest helminths can prevent or improve colitis, prompting investigation into their therapeutic potential.

Purpose of the Study:

  • To evaluate the efficacy and safety of Trichuris suis ova as a therapeutic agent for ulcerative colitis.
  • To determine if helminth therapy can improve disease activity in patients with active UC.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial was conducted with 54 patients diagnosed with active ulcerative colitis (Ulcerative Colitis Disease Activity Index ≥4).

Related Experiment Videos

  • Participants received either 2500 Trichuris suis ova or a placebo orally every two weeks for a total of 12 weeks.
  • The primary outcome measure was improvement in the Ulcerative Colitis Disease Activity Index.

    • Main Results:

    • After 12 weeks, 43.3% of patients receiving Trichuris suis ova showed improvement in their Disease Activity Index, compared to 16.7% in the placebo group (P = .04).
    • Significant improvement was also observed using the Simple Index by week 6.
    • No significant side effects were reported during the trial.

    Conclusions:

    • Trichuris suis ova therapy appears to be a safe and effective treatment option for patients experiencing active ulcerative colitis.
    • The findings support further research into helminthic therapy for inflammatory bowel diseases like UC.